Efficacy and safety of biotechnological drugs for the treatment of moderate-to-severe psoriasis in the elderly population: a single-center, Italian experience.

Background: Demographic changes impose a number of issues regarding the biological treatment of elderly patients with moderate-to-severe psoriasis.

Patients And Methods: A retrospective, single-center study was conducted on patients aged 65 years or older with moderate-severe psoriasis who had been undergoing treatment with biologic drugs for at least 60 weeks.

Results: A total of 168 patients aged 65 years or older with moderate-to-severe psoriasis undergoing biologic therapy were retrieved: 45 were women and with a mean age of 73.